Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS

Elisa Caiola, Laura Brunelli, Mirko Marabese, Massimo Broggini, Monica Lupi, Roberta Pastorelli

Research output: Contribution to journalArticlepeer-review


KRAS mutations in non-small-cell lung cancer (NSCLC) patients are considered a negative predictive factor and indicate poor response to anticancer treatments. KRAS mutations lead to activation of the PI3K/akt/mTOR pathway, whose inhibition remains a challenging clinical target. Since the PI3K/akt/mTOR pathway and KRAS oncogene mutations all have roles in cancer cell metabolism, we investigated whether the activity of PI3K/akt/mTOR inhibitors (BEZ235 and BKM120) in cells harboring different KRAS status is related to their metabolic effect. Isogenic NSCLC cell clones expressing wild-type (WT) and mutated (G12C) KRAS were used to determine the response to BEZ235 and BKM120. Metabolomics analysis indicated the impairment of glutamine in KRAS-G12C and serine metabolism in KRAS-WT, after pharmacological blockade of the PI3K signaling, although the net effect on cell growth, cell cycle distribution and caspase activation was similar. PI3K inhibitors caused autophagy in KRAS-WT, but not in KRAS-G12C, where there was a striking decrease in ammonia production, probably a consequence of glutamine metabolism impairment. These findings lay the grounds for more effective therapeutic combinations possibly distinguishing wild-type and mutated KRAS cancer cells in NSCLC, exploiting their different metabolic responses to PI3K/akt/mTOR inhibitors.

Original languageEnglish
Pages (from-to)51462-51472
Number of pages11
Issue number32
Publication statusPublished - Aug 1 2016


  • BEZ235
  • BKM120
  • KRAS
  • Metabolomics

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS'. Together they form a unique fingerprint.

Cite this